Note: Single-source report; awaiting corroboration.
A clinical trial funded by the National Institutes of Health compared two opioid treatment approaches for infants with moderate to severe neonatal opioid withdrawal syndrome (NOWS). This condition results from opioid exposure during pregnancy and causes withdrawal symptoms after birth. The study included 383 infants managed with the family-centered Eat, Sleep, Console (ESC) method. They were divided into groups receiving either scheduled opioid dosing or symptom-based dosing, where medication was given only when withdrawal signs reached a set threshold. Safeguards were included to prevent undertreatment.
Results showed that infants treated with symptom-based opioid dosing were able to stop medication sooner and were ready for discharge about two days earlier than those on the traditional scheduled tapering regimen. The symptom-based approach did not show these benefits for infants managed with the traditional Finnegan scoring system instead of ESC.
After the trial, several participating hospitals adopted the symptom-based dosing approach, suggesting potential for broader clinical use. Lead author Dr. Lori Devlin noted that adjusting treatment to withdrawal severity may speed recovery and reduce opioid exposure in newborns.